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The integrity of a cell is regulated by internal sensors and extra-
cellular signals. When a cell loses functional contact or ade-
quate interaction with its surroundings or detects irreparable 
internal damage, apoptosis is activated. [1]. Mammals have 
developed another mechanism that allows the organism to ac-
tively drive individual cells to self-destruction. This type of “in-
structive” apoptosis is especially relevant in the immune sys-
tem, where it has been characterized in detail. Nevertheless, it 
is also becoming highly relevant in other systems such as the 
nervous system.
1 Death receptors
Death receptors (DRs) belong to the tumor necrosis factor (TNF) 
superfamily, which comprises receptors involved in proliferation, 
differentiation, and apoptosis. DRs are type I integral membrane 
proteins with a conserved extracellular domain containing two to 
four cysteine-rich pseudo-repeats (CRD), a single transmem-
brane region, and a conserved intracellular death domain (DD) of 
about 80 amino acids that binds to adaptor proteins and initiates 
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Resum
L’apoptosi és un procés fisiològic que controla el nombre de 
cèl·lules en organismes superiors. L’apoptosi està estrictament 
regulada i s’ha vist que està implicada en la patogènesi d’algu-
nes malalties del sistema nerviós. En aquest sentit, un excés 
de mort cel·lular contribueix a les malalties neurodegenerati-
ves, mentre que, el seu dèficit és una de les raons del desenvo-
lupament de tumors. El punt principal de regulació del procés 
apoptòtic és l’activació de les caspases, cisteïna-proteases 
que tenen especificitat pels residus aspàrtic. Les caspases es 
poden activar per dos mecanismes principals: (1) alliberament 
de citocrom C dels mitocondris alterats al citoplasma i (2) l’ac-
tivació dels receptors de la membrana anomenats receptors 
de mort (DR, de l’anglès death receptor). Aquests receptors 
s’han caracteritzat extensament en el sistema immunitari, men-
tre que en el sistema nerviós les seves funcions són encara 
desconegudes. El present article se centra en el paper dels DR 
en la patogènesi de malalties neurodegeneratives i suggereix el 
seu potencial des del punt de vista terapèutic. També es des-
criuen diverses molècules intracel·lulars caracteritzades per la 
seva habilitat en la modulació dels DR. Entre elles, presentem 
dues noves proteïnes – lifeguard i FAIM – que s’expressen es-
pecíficament al sistema nerviós.
Paraules clau: apoptosi · receptors de mort · 
neurones · FAIM · LFG
Abstract
Apoptosis is a strictly controlled, physiological process by 
which the number of cells in metazoan organisms is regulated. 
Recently, it has been shown that apoptosis is involved in the 
pathogenesis of certain nervous system diseases. Excess cell 
death is thought to contribute to neurodegenerative disorders 
while defects in apoptosis lead to the development of neopla-
sias. Regulation of apoptosis primarily occurs through the acti-
vation of caspases, cysteine proteases that specifically cleave 
aspartic acid residues. Caspases are activated by two mecha-
nisms: (1) release of cytochrome C from mitochondria to the 
cytoplasm and (2) activation of plasma membrane death re-
ceptors (DRs). These latter proteins have been widely charac-
terized in the immune system, whereas in the nervous system 
their function remains elusive.
In this article we focus on the role of DRs in the pathogenesis 
of neurodegenerative diseases and on the potential of these 
proteins as therapeutic targets. We also discuss several intrac-
ellular molecules that modulate DR activation. Among these, 
we introduce two novel proteins, Lifeguard and FAIM, which 
are specifically expressed in the nervous system. 
Keywords: apoptosis · death receptors · neurons · 
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apoptosis [2]. To date, eight DRs containing DDs have been 
characterized: TNF receptor 1 (TNFR1; also known as DR1, 
CD120a, p55, and p60), Fas (DR2, APO-1, and CD95), DR3 
(APO-3, LARD, TRAMP, and WSLT), TNF- related apoptosis-in-
ducing ligand (TRAILR1; DR4 or APO-2), TRAILR2 (DR5, KILLER 
and TRICK2), DR6, ectodysplasin A receptor (EDAR), and the 
nerve growth factor receptor (p75NTR). The DDs of these pro-
teins allow them to recruit adaptor molecules and to initiate acti-
vation of the apoptotic signaling cascade [3]. Ligands for these 
receptors are structurally related molecules that also belong to 
the TNF superfamily and include FasL, which binds to Fas; TNFα 
and lymphotoxin α, which bind TNFR1; TL1A, also called VEGI 
(vascular endothelial cell growth inhibitor), which interacts with 
DR3; and TRAIL, which activates DR4 and DR5 [4]. DR ligands 
cans also interact with “decoy” receptors (DcRs), which do not 
have DDs and therefore do not form death signaling complexes. 
Four DcRs have been described: TRAILR3 (also called DcR1), 
TRAILR4 (DcR2), DcR3, and osteoprotegrin (OPG).
2 Death receptor signaling pathways
Once death ligands (DLs) bind to their specific receptors, two 
different types of signaling complexes can be formed. The first, 
called DISC (death-inducing signaling complex), is typical of 
Fas, TRAILR1, and TRAILR2 receptors. DISC It leads directly to 
the recruitment and activation of caspase-8, which is the initia-
tor caspase of the apoptotic process. The second type of com-
plex is specific for TNFR1, DR3, and DR6 receptors and re-
cruits a different set of adaptor proteins. Depending on the 
complex composition, Fas and TNFR can signal cell death or, 
surprisingly, cell survival (see below and Figure 1). 
2.1 Fas signaling
FasL binds between the second and third CRD of the ligand-
binding domain of Fas and induces clustering of the receptor at 
one pole of the cell [5], while, simultaneously, the DISC forms 
within the cell. During DISC formation, the adaptor FADD (Fas-
associated death domain), procaspase-8 interacts with the Fas 
receptor through homotypic contacts. Local high concentrations 
of procaspase-8 induce autoproteolytic activation, which results 
in the formation of heterotetramers of two large subunits (p18) 
and two small subunits (p10) of active caspase-8. These are re-
leased into the cytoplasm, where they activate executor caspas-
es such as caspase-3 and caspase-7. Assembly of the Fas-in-
duced DISC differs between cell types. So-called type I cells are 
characterized by a high level of DISC formation and therefore 
strong caspase-8 activation, which allows for direct activation of 
executor caspases. At lower levels of caspase-8, apoptotic sig-
naling requires a mitochondrial amplification loop [7]. In this case, 
Figure 1. Comparison of TNFR1 and Fas signaling. Fas directly recruits FADD, procaspase-8, pro-caspase-10, and the caspase-8/10 regulator c-
FLIP to the death-inducing signaling complex (DISC), resulting in the release of active caspase-8 and -10. This, in turn, induces apoptosis, the default 
pathway for Fas. Alternatively, in Fas apoptosis-resistant cells, Fas induces NF-kB activation. The TNFR1 default pathway activates NF-kB and other 
non-apoptotic pathways (not shown) through the formation of complex I, comprising TNFR1 and NF-kB activating signaling components such as RIP 
and TRAF2. Subsequently, there is transcriptional activation of a number of anti-apoptotic genes, such as c-FLIP and others that prevent the induc-
tion of apoptosis, in part by inhibiting caspase-8 activity. After receptor activation, some of the components of complex I are post-translationally 
modified. These modifications may serve as a cue for the signaling components but not the receptor (not shown) to leave the plasma membrane and 
form complex II (an intracellular DISC) by recruiting the apoptosis-inducing components FADD, procaspase-8, and either procaspase-10 (DISC on) or 
c-FLIP (DISC off). Dark blue bold lines indicate the default pathways, which are survival for TNFR1 and apoptosis for FAS. Only the membrane proxi-
mal events of apoptosis signaling are shown. IKKs IkB kinase complex; death domains are represented in red and death effector domains in blue. 
Barnhart, BC and Peter, ME (2003). The TNF receptor 1: a split personality complex. Cell.114 (2). 148-50
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the few active molecules of caspase-8 process and activate Bid, 
a BH3-only member of the Bcl-2 family. Caspase-8 truncated 
Bid (tBid) is able to induce the release of cytochrome c and thus 
the activation of mitochondrial-based apoptosis [3].
2.2 Signaling by TNFRI
Signaling by TNFα occurs through two receptors, TNFR1 and 
TNFR2, although most of the biological effects are mediated by 
TNFR1 [6]. For more than a decade it has been known that lig-
and binding to TNFR1causes receptor trimerization [7] and re-
lease of the TNFR-inhibiting protein SODD (silencer of death 
domains) from the intracellular domain. This allows recruitment 
of the adaptor protein TRADD (TNFR-associated death domain 
protein), which serves as a common platform for the different 
molecules that execute the distinct functions of TNFα, either cell 
survival or apoptosis. In 2003, Micheau and Tschopp proposed 
a model to explain the detailed mechanisms of TNFR1 signaling 
[8], in which apoptotic signaling requires the formation of two 
successive complexes. The first one recruits TRADD, RIP1, 
TRAF2 (TNFR-associated factor), and IAP1. This complex acti-
vates NF-kB signaling but not apoptosis. NF-kB pathway acti-
vation contributes to blocking apoptotic signals by inducing the 
expression of anti-apoptotic proteins such as IAP1, IAP2, 
TRAF1, TRAF2, and FLIP [9]. Moreover, it seems that NF-kB 
can also block apoptosis by suppressing the constitutive activity 
of the Jun-kinase pathway [10]. If NF-kB activation is strong 
enough, the cell will not die. Otherwise, the first complex disso-
ciates and the second complex forms, in which TRADD and 
RIP1 associate with FADD and procaspase-8. In this complex, 
TNFRI is absent. Subsequently, caspase-8 activates apoptosis 
by a mechanism similar to that of Fas-caspase-8 [8].
3 Death receptors in the nervous system
The role of the extrinsic pathway in the central nervous system 
(CNS) is still poorly characterized. However, there is increasing 
evidence demonstrating that DR signaling participates in nor-
mal development and in a large variety of pathological situa-
tions [11]. 
3.1 Role of DRs in the development of the nervous 
system
Programmed cell death (PCD) is a very relevant phenomenon 
during CNS development since roughly half the neurons that 
are generated during neurogenesis are eliminated by this proc-
ess. PCD is regulated by neurotrophic factors released from 
cells innervated by a given neuronal population. [12]. Since the 
magnitude of neuronal death differs in different neuronal popu-
lations [13], the exact mechanisms regulating the death of 
these cells probably differ as well. 
One of the best systems to study PCD is spinal cord mo-
toneurons. The FasL/Fas system has been clearly implicated in 
the apoptotic cell death of motoneurons induced in vitro by 
trophic factor deprivation, a system thought to recapitulate that 
of PCD in vivo [14]. However, it has not been possible to dem-
onstrate the role of the FasL/Fas system in vivo. Transgenic 
mice expressing a dominant negative form of the Daxx protein 
(essential for Fas-induced cell death) do not show any altera-
tions in spinal cord development, indicating that neither Daxx 
nor any of its associate molecules (Fas, ASK-1, etc.) are signifi-
cantly involved in cell death during spinal-cord development 
[15]. Similarly, Kovac et al. reported that animals carrying either 
mutated Fas (lpr mice) or FasL (gld mice) do not differ from 
wild-type mice with respect to the number of neurons in differ-
ent areas of the hippocampus [16]. It was therefore concluded 
that Fas is not important in the apoptotic cell death that occurs 
during the development of the nervous system, although it can 
not be ruled out that another DR is redundant regarding the 
function of Fas [17]. Particularly, the neurotrophin receptor p75 
(p75NTR) has been implicated in PCD occurring in early stages 
of brain development. 
Although, based on what is known thus far, DRs, with the 
exception of p75NTR, do not seem to have a clear role in the 
apoptosis of embryonic development, they may have other de-
velopmental functions. Recent results have shown that the Fas 
system is involved in the growth of neuronal processes [18]. 
Zuliani and colleagues demonstrated that exogenous FasL 
promotes the branching of neurites in embryonic cortical neu-
rons. Accordingly, it has been reported that pyramidal neurons 
from 5-week-old lpr mice show a retraction of the dendritic tree 
and a loss of dendritic spines [19]. The regulation of neurite 
growth seems to be independent of caspase-8 and the func-
tional DD of Fas and instead to depend on the MEK1/ERK/p35 
pathway [20]. 
3.2 Implication of the DRs in pathologies 
A large number of studies have examined the role of DRs under 
pathological situations. Increased levels of the components of 
the Fas/FasL system and other cytotoxic cytokines such as 
TNFα have been detected in inflammatory, degenerative, trau-
matic, ischemic, and neoplastic processes. 
3.3 Ischemia
Cerebral ischemia is a restriction in the blood supply to the 
brain. The numerous causes include the spontaneous, in situ, 
total occlusion of an artery, after traumatic brain injury, by a re-
duction in arterial diameter of hereditary origin, or by embolism, 
generally of cardiac origin. The magnitude of the damage de-
pends on the duration and severity of the insult. Although most 
of the affected cells will die by necrosis, a slower rate of neuro-
nal death is associated within the so-called penumbral area 
[21]. During the cell-stress response to ischemia, c-Jun N-ter-
minal kinases/stress-activated protein kinases (JNK/SAPKs) 
are activated. JNK/SAPKs are translocated to the nucleus, 
where they activate the transcription factor c-jun, with conse-
quent induction of the expression of target genes such as FasL 
and TNFα [22]. It has also been demonstrated that glial cells 
can contribute to the progression of cell death in the later period 
of ischemia, through the production of nitric oxide or pro-inflam-
matory cytokines [23]. Hypoxia or the presence of reactive oxy-
gen species (ROS) induces the expression of FasL in microglial 
cells [24]. Studies have shown that the levels of FasL and TNFα 
are elevated in post-ischemic brains, as is the capacity of these 
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proteins to induce cell death in primary cultures of neurons. The 
importance of these DLs is reinforced by the resistance of Fas-
deficient mice to post-ischemic neuronal damage [25]. Never-
theless, the role of TNFR1 in vivo is controversial, because in 
some cases it has been observed that the blockade of signaling 
by the receptor reduces the size of the affected area, whereas 
mice deficient in TNFR1, TNFR2, or both have greater ischemic 
damage. With the purpose of clarifying the function of these re-
ceptors, Martin-Villalba and others evaluated the resistance of 
TNFα- and FasL-deficient mice to primary ischemic damage 
and the subsequent inflammatory reaction, using a model of oc-
clusion of the middle cerebral artery. Their results demonstrated 
that hybrid TNFα- and FasL-deficient mice were more resistant 
to damage induced by arterial occlusion. These results were re-
inforced by observations that, in control mice injected with a 
combination of antibodies to neutralize FasL and TNFα, infarct 
volume was reduced by 70%. A smaller inflammatory response, 
as shown by a reduced invasion of granulocytes, was also ob-
served. The combination of protection against primary ischemic 
damage along with a reduced inflammatory response resulted 
in longer survival of TNFα- FasL-deficient animals. Moreover, 
the mice recovered locomotive function to an extent practically 
indistinguishable from that of animals that had been operated 
on but without arterial occlusion [26]. 
3.4 Inflammatory diseases 
Fas also appears to play a role in inflammatory diseases such 
as multiple sclerosis (MS). MS is an autoimmune pathology that 
affects the brain and spinal cord and is mediated by T-lym-
phocytes. Small areas of inflammation are formed and correlate 
with demyelinization caused by the specific death of oli-
godendrocytes. This progressive demyelinization interrupts the 
transmission of electric signals affecting different areas of the 
CNS, leading to alterations in sensation, visual problems, mus-
cle weakness, depression, difficulties with coordination and 
speech, severe fatigue, cognitive impairment, problems with 
balance, overheating, and pain [27]. An experimental model 
widely used for the study of the MS is experimental allergic en-
cephalomyelitis (EAE). EAE is induced by the injection of mye-
lin-specific peptides into mice. After 10–14 days, the animals 
develop a loss of muscular tone in their tails and coordinated 
muscular movements deteriorate [28]. In this experimental 
model, the Fas/FasL system produces two different responses: 
(1) It acts as an inducer of cell death, since T-cells expressing 
FasL on their surfaces target those cells with surface expres-
sion of Fas, such as neurons and oligodendrocytes. The injec-
tion of specific anti-FasL antibodies just after the acute phase 
of EAE destabilizes the Fas/FasL system and results in a clini-
cal improvement of symptoms [29]. (2) The immune system ex-
erts protective functions in later phases of EAE, regulating au-
toimmune complications that arise after the appearance of 
self-antigens [11]. 
3.5 Traumatic brain injury
Traumatic brain injury (TBI) represents one of the main causes 
of death in the population below 45 years. Cellular damage is, 
in part, due to glutamate toxicity and a deregulation of calcium 
homeostasis [30]. Moreover, experimental evidence has shown 
that DRs participate in neuronal death. Data from animal mod-
els as well as from patients with severe trauma showed that TBI 
induces formation of the DISC complex and promotes activa-
tion of the caspase cascade. Studies of Fas and FasL expres-
sion showed co-localization in neurons, where the assembly of 
DISC may cause cell death by an autocrine mechanism. [31]. 
High levels of TNFα have been detected in extracts of trau-
matic cerebral cortex and in the cephalo-rachidian fluid of pa-
tients with TBI [32]. In experimental models, an increase in 
TNFR1 mRNA and protein beginning 1 h post-trauma was ob-
served [33]. Therefore, TNFR1 and TNFα may constitute suita-
ble targets for therapeutic strategies [34]. 
Another pathology associated with trauma is spinal cord in-
jury (SCI). One of the main therapeutic goals is the recovery of 
motility after injury, by reestablishing neuronal connections. 
This can reportedly be attained by blocking FasL with specific 
antibodies. The mechanism behind this effect could involve a 
greater regenerative capacity of axons or the blockade of ap-
optosis by neurons and oligodendrocytes. [35]. 
3.6 Neurodegenerative diseases
Neurodegenerative diseases results from the death of specific 
neuronal populations. Alzheimer’s disease (AD) is characterized 
by the deposition of β-amyloid fibers and an extensive loss of 
neurons. Many efforts have focused on the mechanism of fiber 
deposition, but it is still not clear how the formation of these so-
called senile plaques results in neuronal death. Peculiarly, it 
seems that the loss of neurons is selective for certain areas of 
the brain (frontal cortex and hippocampus), whereas subcorti-
cal areas and the cerebellum remain unaffected [36]. Apoptotic 
features have been observed in affected neurons [37]. Among 
the different stimuli that induce the neuronal death seen in AD, 
the activation of DRs in microglial cells seems to be responsible 
for the neurotoxic effects. The β-amyloid fibers induce the pro-
duction of cytokines, for example TNFα, through a tyrosine-ki-
nase signaling-dependent mechanism [38].
Along with the production of cytokines, the formation of 
ROS contributes to neurotoxicity [39]. In mice overexpressing 
the human amyloid precursor protein, increased expression of 
Fas led to increased neuronal death. By contrast, Fas expres-
sion is reduced in hybrid mice expressing the protein superox-
ide dismutase (SOD), an enzyme able to process ROS to less 
toxic products [40]. These results suggest that antioxidant 
therapy may provide a strategy for reducing Fas expression. 
Unlike the neurotoxic effects mediated by DRs in neurode-
generative diseases, these proteins play a neuroprotective role 
in Parkinson’s disease (PD). PD involves a loss of dopaminergic 
neurons of the substantia nigra pars compacta, giving rise to 
the characteristic symptoms of tremor, bradykinesia, rigidity, 
and postural instability. A well-established model of PD in ro-
dents and primates consists of the administration of 1-methyl-
4-fenil-1,2,3,6-tetrahidropiridium dopaminergic toxin (MPTP) 
[41]. MPTP toxin metabolizes into 1-methyl-4-phenylpyridinium 
(MPP+), which by selectively concentrating in dopaminergic 
neurons causes the death of these cells. In patients with PD, 
both Fas expression and the anchored form to FasL are dimin-
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ished [42], whereas the soluble form of FasL, which block Fas 
signaling, is increased [43]. Landau et al. demonstrated that in 
Fas-deficient mice (lpr) treated with suboptimal doses of MPTP 
there is a dramatic loss of dopaminergic neurons whereas the 
same doses do not cause alterations in wild-type mice. Neuro-
nal loss is accompanied with hypokinesia, tremors, and disco-
ordination. In vitro, it has also been demonstrated that Fas acti-
vation is able to protect against MPTP-induced cell death by a 
caspase-8 independent mechanism. However, other experi-
ments carried out in animal models of PD showed an increase 
in TNFα shortly after MPTP administration. Mice deficient in 
TNFR1 and TNFR2 were completely resistant to death induced 
by MPTP, implying that TNFα is an effector of the neurodegen-
erative process [44].
4 Death receptors antagonists
The function of the DRs can be modulated by posttranslational 
modifications of the receptor, such as glycosylation [45], or by 
interfering in the apoptotic cascade. Table 1 lists the proteins 
that have been described to antagonize DR function. The table 
does not include those molecules that antagonize DR indirectly, 
that is, by interfering in the mitochondrial or intrinsic pathway, 
such as the anti-apoptotic Bcl-2 family members and IAPs. 
4.1 FLICE inhibitory protein
Searches for proteins able to interact with Fas DD have led to 
the isolation of a new protein family characterized by the pres-
ence of dead effector domains (DEDs). These proteins, collec-
tively called viral inhibitors of FLICE (vFLIPs), have been detect-
ed in several viruses, including herpesvirus Saimiri, herpesvirus 
human 8, and the herpesvirus associated with Karposi’s sar-
coma. Up to 13 different splicing variants have been described 
but only three are translated into proteins. Structurally, all iso-
forms consist of two DEDs, which are similar to the N-terminal 
end of caspase-8. The C-terminal of FLIPL also consists of two 
caspase-like domains (p20 and p12), although they do not 
have the amino acids critical for caspase activity. FLIPS and 
FLIPR [46] contain DEDs at their C-terminal ends; the DED in 
FLIPR is shorter than the one in FLIPS and different from FLIPL, 
caspase-8, and caspase-10 [47]. Generally, all FLIP isoforms 
play an anti-apoptotic role in DR-induced apoptosis. Results 
obtained from loss-of-function experiments for FLIPS and for 
FLIPL, together [48] or separately [49], showed that FLIP has 
inhibitory consequences in the processing of caspase-8. In ad-
dition, mouse embryonic fibroblasts isolated from FLIP-defi-
cient mice showed high sensitivity to DR-induced apoptosis 
[48]. Once FLIPL is recruited to the DISC, it is processed into 
two subunits: p43, which remains in the DISC, and p12, which 
is released into the cystosol. In the presence of FLIPL, cas-
pase-8 is also processed into two fragments of p43 and p41 
kDa, whereas a p10 subunit is released to the cytoplasm. Ac-
cording to the model of autocatalytic cleavage induced by 
proximity, proposed for caspase-8 [50], autocatalytic activation 
takes place first; this is followed, in the presence of an adjacent 
caspase domain, by a transcatalytic cut that leads to complete 
activation of the caspase. The resulting heterotetramer, com-
posed of two p18 and to p10 subunits, is then ready to cleave 
downstream substrates. If the adjacent molecule in this model 
is FLIPL, without a functional caspase domain, the autocata-
lytic cut of caspase-8 will occur but not the transcatalytic cut, 
therefore preventing total activation of the enzyme [47].
Besides studies on the anti-apoptotic function of FLIP, the 
phenotype of FLIP null mice has opened up new perspectives. 
These mice die at day 10.5 of embryogenesis due to a failure in 
cardiac development not related to a lack of apoptosis, sug-
gesting apoptosis-independent roles for FLIP. Moreover, FLIP 
is expressed in different cell types, ones unrelated to DR sensi-
tivity [51]. Little or almost nothing is known about the physio-
logical function of FLIP in the nervous system. Its expression in 
cortical neurons during development has been detected [52] 
Table 1. Main death receptors antagonists
Name Description Expresse d in NS References Comments
A20 Zinc Finger Protein A20 YES [66],[67],[68],[69]
BAR Bifunctional Apoptosis Regulator YES [701,[71],[72]
FAIM Fas Apoptosis Inhibitory Molecule YES [551,[561,[57] FAIML exclusivve of NS
FAP-1 Fas Associated Phosphatase-1 YES [73],[74],[75],[76],[77],[78]
FLIP FLICE Inhibitory Protein YES [59],[60],[61],[62],[63],[64],[65]
LFG Lifeguard YES [51],[52],[53],[54] Exclusive of NS
PEA-15 Phosphoprotein Enriched in Astrocytes YES [79],[80],[81],[82],[83]
SODD Silencer Of Death Domains YES [84],[85],[86],[87]
SUMO-1 Small Ubiquitin-related Modifier 1 YES [88],[89],[90],[91]
BTK Burton’s tyrosine kinase NO [92],[93]
Toso Cell surface protein NO [941,[95]
E6 Viral protein NO [96],[97]
E3 RID Adenoviral protein NO [98]
HPV E7 Adenoviral protein NO [99]
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although expression has not been correlated with the resist-
ance or sensitivity to Fas of the different neuronal populations. 
In granular neurons of the cerebellum, which are resistant to 
Fas, it has been observed that FLIP expression diminishes dur-
ing in vitro differentiation while LFG, another recently described 
Fas antagonist, is up-regulated [53]. Therefore, FLIP expres-
sion could regulate the activities of DRs during the develop-
ment of distinct cellular types and during specific periods. 
4.2 Zinc finger protein A20 
A20, one of the primary response genes to TNFα, encodes a 
protein of 80 kDa, with a C-terminal domain that contains sev-
en  zinc finger motifs (Cys2/Cys2) [54]. This protein is able to 
inhibit TNFα- and interleukin-1-induced apoptosis. The ability 
to block the signaling induced by these inflammatory cytokines 
constitutes a mechanism of negative regulation in the inflam-
matory response [55]—a function that is essential during devel-
opment since A20-deficient mice die prematurely from severe 
inflammation and cachexia [56]. Although the mechanisms of 
molecular action are still unclear, it seems that A20 interferes in 
TRADD and RIP binding to TNFRI [57].
4.3 Bifunctional apoptosis regulator 
The bifunctional apoptosis regulator (BAR) protects cells 
against extrinsic or intrinsic apoptotic stimuli. It is a protein of 
450 kDa, located in the endoplasmic reticulum of neurons [58]. 
BAR was firstly described in a two-hybrid assay aimed at iden-
tifying Bax antagonists. The protein contains a sterile alpha 
motif (SAM) in the middle part of its structure that allows its in-
teraction with anti-apoptotic Bcl-2 family members such as 
Bcl-2 or BclXL, but not with Bax or Bak [59]. In addition to the 
SAM domain, BAR contains a domain similar to the DED. That 
domain interacts with caspase-8, thus inhibiting the extrinsic 
pathway. One possibility is that BAR captures fragments of ac-
tive caspase-8 into intracellular membranes, neutralizing the 
enzyme’s effect and preventing further cleavage of vital sub-
strates [60].
4.4 Fas-associated phosphatase-1 
Fas-associated phosphatase-1 (FAP-1) was identified in a two-
hybrid assay to detect proteins associated with Fas. FAP-1 en-
codes a tyrosine phosphatase that interacts with the last 15 
amino acids of the Fas C-terminus, through a PDZ3 domain. 
FAP-1 overexpression reduces FasL-induced cell death in T-
lymphocytes [61] and in other human cell lines. One of the an-
tagonistic mechanisms that have been proposed is based on 
the capacity of FAP-1 to dephosphorylate tyrosines that are im-
portant for the recruitment of adaptor proteins (e.g., FADD) to 
Fas [62, 63]. Later studies proposed that strong expression of 
FAP-1 diminishes the presence of Fas in the plasma membrane 
but increases levels of the protein in intracellular reservoirs. Ex-
periments with dominant negatives of FAP-1 or in which endog-
enous levels of the phosphatase are reduced showed increased 
transport of Fas to the surface of the plasma membrane [64]. 
FAP-1 has been identified as one of the genes responsible for 
tumor resistance to Fas-induced cell death. [65]. This effect could 
also be the basis of the high aggressiveness and resistance to 
treatment of astrocytomas [62] or colon carcinomas [66]. 
4.5 Phosphoprotein enriched in astrocytes-1 (PEA-15) 
PEA-15 is a 15-kDa phosphoprotein ubiquitously expressed in 
cells but enriched in astrocytes [67]. It contains a DD that al-
lows its interaction with Fas [68] and TNFR1. PEA-15 is able to 
inhibit Fas-induced apoptosis but enhances TNFα-induced cell 
death. However, results in PEA-15 deficient mice shows that 
PEA-15 increases astrocyte survival after exposure of the cells 
to TNFα [69]. Phosphorylation at Ser-104 blocks the interac-
tion between PEA-15 and ERK, whereas phosphorylation at 
Ser-116 is necessary for the interaction of PEA-15 with FADD 
and the capacity of this complex to inhibit apoptosis [70]. 
4.6 Silencer of death domains (SODD) 
It has been demonstrated that the increase in the density of 
receptors containing DDs in certain areas of the plasma mem-
brane cause DD aggregation and activation of the caspase 
cascade in the absence of ligand binding. The fact that DRs are 
commonly expressed on the cell surface, where they form oli-
gomers [71], suggests the existence of molecules that maintain 
them in their inactive state. SODD (silencer of death domains) 
was isolated as a DR3-binding protein. It is 457 amino acids 
long and also binds DR3, TNFR1, and TNFR2 but not Fas, 
DR4, or DR5. SODD blocks all TNFR1 functions, including ap-
optosis and activation of the NF-kB or JNK pathways in vitro 
[72]. SODD null mice appear normal, thus suggesting the exist-
ence of redundant or compensatory mechanisms, such as the 
A20 or TRAF2 proteins [73]. 
4.7 Small ubiquitin-related to modifier 1
Small ubiquitin-related to modifier 1 (SUMO) is another mole-
cule that interacts with the intracellular domain of Fas. It con-
sists of 101 amino acids and has high homology with ubiquitin 
[74]. SUMO overexpression protects cells from both Fas- and 
TNFRI-induced apoptosis; however, the exact mechanism re-
mains unknown. SUMO1 is able to induce post-translational 
modifications that affect the stability or intracellular location of 
many proteins, among them those participating in apoptotic 
pathways, such as caspase-2, caspase-7 [75], caspase-8 [76], 
protein ASK-1 [77], and the NEMO/IKKγ complex.
4.8 Lifeguard 
Lifeguard (LFG) was cloned in 1999. The protein protects 
against Fas-induced cell death but not against death induced 
by other DRs such as TNFR1 [78]. A comparison with se-
quences in the databases showed that LFG is the human ho-
mologous of rat NMP35 (neural membrane protein 35) [79]. 
The latter protein was identified by differential display experi-
ments targeting genes that are regulated during development 
of the rat sciatic nerve. NMP35 is predominantly expressed in 
the nervous system. Expression of the protein increases during 
development, reaching maximum levels in the adult. 
The first attempts to understand LFG function were carried 
out in HeLa and Jurkat cell lines, both of which are sensitive to 
FasL-induced apoptosis. LFG was reported to be responsible 
for maintaining the resistance of neurons to Fas in the cerebel-
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lum [53]. We subsequently demonstrated that LFG regulates 
Fas activity in other neuronal populations, such as cortical neu-
rons [80]. In those studies we also showed that an endogenous 
decrease of LFG in granular neurons of cerebellum and cortical 
neurons sensitizes these neurons to Fas-induced apoptosis. In 
summary, these results locate LFG as one of the main proteins 
responsible for the maintenance of Fas-resistance in neurons, 
particularly when other antagonists, such as FLIP, are not or 
poorly expressed.
4.9 Fas apoptosis inhibitory molecule (FAIM) 
Fas apoptosis inhibitory molecule (FAIM) was first identified as 
a Fas antagonist in B-cells. FAIM has been highly conserved 
during the evolution, from Caenorhabditis elegans to humans 
[81]. A longer, alternative splicing isoform of the protein but with 
unknown function was identified and named FAIML. FAIMS is 
widely expressed, including in the nervous system. We demon-
strated that overexpression of FAIMS, but not FAIML, enhances 
NGF-induced neurite outgrowth in different neuronal popula-
tions through activation of the NF-kB pathway. No anti-apop-
totic function has been described in the nervous system. How-
ever, FAIML is specifically expressed in neurons and its 
expression is regulated during development. FAIML does not 
affect neurite outgrowth, nor does it modulate NF-kB activa-
tion. However, cells overexpressing FAIML are resistant to ap-
optotic cell death induced by DRs such as Fas or TNFR1. Re-
duction of endogenous expression shows that endogenous 
FAIML protects primary neurons against DR-induced cell death. 
FAIML normally binds the Fas receptor and prevents its activa-
tion. FasL binding to Fas induces the release of FAIML from 
Fas, allows the binding of FADD and caspase-8,  and leads to 
apoptosis activation [82]. 
5 Conclusions and prospectives
Signaling pathways controlling neuronal death and survival are 
crucial for the normal development and function of the nervous 
system. In contrast to most cell types, neurons survive for the 
lifetime of the organism and therefore require powerful intracel-
lular mechanisms to antagonize cell death stimuli. 
Death receptors are widely expressed in the nervous sys-
tem, in both neurons and glial cells. However, DR-induced ap-
optosis does not seem to play a role in regulating cell death in 
the developing nervous system, although, under certain patho-
logical conditions, DR-induced apoptosis might be involved in 
cell death of mature neurons. The deleterious functions of DRs 
in the nervous system require a fine tuning mechanism, which 
might be achieved by different regulatory proteins. Restriction 
of DR-mediated signaling to specific neurons could control 
neuronal development and the selectivity of neuronal loss in 
degenerative diseases. In addition, under certain pathological 
conditions, DRs are clearly involved either in inducing or pre-
venting apoptosis.
Further research efforts are needed to expand our under-
standing of the molecular basis of DR activity regulation in the 
nervous system. Such efforts will provide a starting point for the 
development of new therapeutic strategies for DR-associated 
neuropathologies.
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